Wire open Last filed Camurus starts Phase 2b trial of monthly semaglutide depot CAM2056 RSS
Peptide Zone

Peptide medicine news,
filed as it happens.

Morning wire

Peptide medicine news filed as it happens

Peptide Zone is a news wire for peptide medicines such as GLP-1 drugs, amylin analogues and peptide vaccines. Each story covers one regulator decision, trial readout, industry deal or safety review, names its primary source and says what comes next. Nothing here is medical advice. About the newsroom

RoutineTRLNews

Camurus starts Phase 2b trial of monthly semaglutide depot CAM2056

Camurus says LUNAR-2 will test its monthly semaglutide depot CAM2056 against placebo in 150 people with obesity or overweight. Its earlier data came from 80 people, and the new trial will not compare the depot with weekly injections.

LUND, SWEDEN

9.3% vs 5.2%Phase 1b weight loss at day 85 on CAM2056 versus weekly semaglutide, per Camurus
  1. What's newCamurus dosed the first patient in LUNAR-2, a placebo-controlled Phase 2b trial of its monthly semaglutide depot CAM2056 in 150 adults with obesity or overweight.
  2. Why it mattersA monthly semaglutide could replace weekly injections, but so far the only efficacy data come from an 80 person, roughly 12 week Phase 1b study reported by the company.
  3. What's nextCamurus expects LUNAR-2 results in the first half of 2028. The trial compares CAM2056 with placebo only, so it will not show whether monthly dosing beats weekly semaglutide.

Latest on the wire

Full wire

The 60-second briefing

Five things filed most recently

  1. SAF · 4 Nov 2026A UK GP urged Mounjaro and Wegovy users to put used needles in sharps bins, after the BBC reported needles and sharps containers turning up at a Coventry recycling plant.
  2. SAF · 4 Nov 2026A 2 Minute Medicine brief on 2 Nov 2026 highlighted FDA category 2 entries that cite deaths in studies of GHRP 2 and ipamorelin. The FDA dated those entries 29 Sep 2023; they are not a new agency action.
  3. IND · 4 Nov 2026Ahead of Novo Nordisk's 4 November quarterly report, Jyske Bank said it expects the company to raise the floor of its 2026 outlook, which now allows declines of up to 6% in adjusted sales and operating profit.
  4. REG · 4 Nov 2026The Advertising Standards Authority banned two Voy ads and one ad each from Juniper and MedExpress, ruling they promoted prescription only oral weight loss medicines to the public without naming them.
  5. TRL · 3 Nov 2026Zeus Hygia, supplier of the berberine extract Metaberine, said its published 36 person crossover trial should not be read as weight loss evidence, though it reported higher natural GLP 1 and lower glucose.

By the numbers

The one figure each story turns on.

20.9% vs 9.4%Average weight loss at 80 weeks on the higher retatrutide dose versus Ozempic, per Lilly TRL · 28 OCT · Retatrutide Ozempic trial shows bigger A1C drop and double the weight loss 28.7%average weight loss on the highest dose after 68 weeks TRL · 11 DEC · Retatrutide posts the largest average weight loss yet in a phase 3 trial 62.9%of treated patients saw liver inflammation resolve without fibrosis worsening, vs 34.3% on placebo REG · 15 AUG · Wegovy gets accelerated approval for fatty liver disease with scarring 20.2%average weight loss on tirzepatide vs 13.7% on semaglutide after 72 weeks TRL · 11 MAY · Tirzepatide beats semaglutide on weight loss head to head 1stprescription drug approved to treat obstructive sleep apnea in adults with obesity REG · 20 DEC · FDA clears tirzepatide as the first medicine for obstructive sleep apnea 6Unapproved peptides HHS will let 503A pharmacies compound under enforcement discretion SAF · 01 NOV · HHS peptide compounding policy splits pharmacists and pharmacologists

Threads we are following

Storylines that span months. Each dot is a story, placed by date.

Thread · 4 stories

Compounded copies and the rules around them

What can people legally get, and how do regulators react when demand outruns supply?

Dec 2024Nov 2026

  • 21 MARSemaglutide copies arrive as key patents lapse outside the US and Europe
  • 06 JUNEU safety committee adds a rare eye condition to semaglutide warnings

Thread · 6 stories

The incretin race

Who ends up with the most weight loss, the fewest side effects and the easiest dosing?

Dec 2024Nov 2026

  • 22 DECThe first GLP 1 pill for weight management gets the green light
  • 07 AUGThe weight loss pill that is not a peptide posts its first obesity readout

Thread · 4 stories

Beyond the scale

Which organ benefits hold up in outcome trials, and which do not?

Dec 2024Nov 2026

  • 24 NOVWhy semaglutide failed to slow Alzheimer's in the EVOKE trials
  • 28 JANSemaglutide wins a kidney label after the FLOW outcome trial

Desk fronts

REGRegulators10
TRLTrials24
INDIndustry15
SAFSafety22
EXPExplainers4

Where this news came from

Primary source type of every story on the wire. How we label sources

  • Regulator14
  • Journal10
  • Company release20
  • Conference8
  • Our newsroom23